🔗 Share this article

While the United States continues making historic changes to its immunization recommendations, a particular individual appears somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by casting doubt on Covid vaccines throughout the pandemic and has focused upon alleged deaths after COVID-19 vaccination in her brief time at the FDA.

Planned Shifts to Childhood Immunization Program

Public health authorities had intended to unveil major changes to the pediatric immunization program in December, bringing the US with the Danish immunization schedule, it is understood – a substantial departure that would put the US out of step with many the international standard with little proof for improved outcomes. The planned update has been pushed back until the coming year.

Instead of Vinay Prasad, Høeg is set to speak at the meeting. She was recently named temporary leader of the FDA’s CDER, the fifth person to run the office this year.

A New Direction at the Regulatory Body

This interim role may indicate a tighter collaboration between the drug and vaccine branches as Høeg and Prasad strengthen their influence at the regulatory agency – and it suggests a renewed priority upon reevaluating previously authorized vaccines at the FDA.

Høeg has frequently advocated for ending certain childhood shot schedules in the US in order to be more in line with Denmark, a society with universal health coverage and a number of inhabitants about the population of Wisconsin’s.

In her initial comments, she has continued to focus on vaccines – typically the domain of Prasad, chief of the FDA’s vaccine center – rather than drug regulation.

Questions Over Background

Dr. Høeg has no obvious track record in drug development, approval processes or leadership, which has been customary for former heads of the biologics center. She has been employed at the FDA as a senior adviser to the commissioner and the vaccine center since March.

“It seems she lacks to have the necessary background” for overseeing the CDER, said Dr. Jonathan Howard. “She lacks experience running a scientific study. She is not versed in running a large organization. She has no expertise in pharmaceutical oversight.”

Former heads of CBER would “grasp legal statutes and the underlying principles of medication creation”, said Janet Woodcock. “Objectively, she doesn’t have the type of experience that previous people who led CBER have had.”

This division has an enormous range of responsibilities at the FDA, Woodcock emphasized.

“Many people just pays attention on the novel medication approvals, but the off-patent medication office authorizes a multitude of generic medications. There’s a biosimilars program, OTC medication office and more, and all of those must be managed,” Dr. Woodcock noted. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to bite you.”

There is also, a substantial management aspect to the job, which supervises more than 5,000 employees. “It is a huge leadership role, if you do it right,” she concluded.

Response and Controversial Policies

When asked about inquiries about Høeg’s fitness for the role and whether this assignment signifies more teamwork among FDA leaders on immunizations, a representative stated that the “concerns stem from incorrect assumptions”.

“This background is consistent with the responsibilities of her role,” the spokesperson said, pointing to the time Høeg spent counseling the FDA commissioner on “pharmaceutical safety and approval science, including computerized risk analysis and immunization monitoring”.

As acting director, Dr. Høeg assumes responsibility for the agency head's new priority voucher program, a disputed rapid drug-approval program that reportedly troubled her preceding directors. “By what process are these therapies being selected for this expedited pathway? Who makes the decisions?” Howard said. “There is a lot of lack of transparency going on at the regulatory body right now.”

Broadly speaking, he said, “the FDA appears to be shifting towards laxer rules of pharmaceuticals, aside from immunizations.”

Established History on Vaccines

With immunizations, Dr. Høeg has a clearer, if troubling, history, critics observe. She published a research paper using unverified volunteer-provided data to assess the incidence of myocarditis following COVID-19 vaccination. She counseled the state of Florida top health official Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccinations are pose a greater threat than they are.

Included in her “policy goals” for the current government included changing regulations for novel immunizations and ending “unnecessary” immunizations, she said post-election on a online show. At the agency, Dr. Høeg has reportedly suggested barring adolescent males from receiving COVID-19 vaccinations.

“She’s an thorough true believer who commences with her conclusions and reverse-engineers to retrofit the science in a highly disingenuous, untruthful fashion,” Howard stated.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of other skeptics, {like|